%22%2F%3E%0A%3Cdefs%3E%0A%3CradialGradient%20id%3D%22paint0_radial_53404_20784%22%20cx%3D%220%22%20cy%3D%220%22%20r%3D%221%22%20gradientUnits%3D%22userSpaceOnUse%22%20gradientTransform%3D%22translate(11.6786%2037.1765)%20scale(40.1126%2040.1123)%22%3E%0A%3Cstop%20stop-color%3D%22%23B4C9EA%22%2F%3E%0A%3Cstop%20offset%3D%221%22%20stop-color%3D%22%23426BBA%22%2F%3E%0A%3C%2FradialGradient%3E%0A%3C%2Fdefs%3E%0A%3C%2Fsvg%3E%0A)
A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder
Study Identifier:
405-201-00014
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
EU CT ID:
N/A
Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Study Contact Information:
N/A
Study Complete
Results Available
Study Protocol
Available Languages: English
Statistical Analysis Plan
Available Languages: English
Study Details
Medical Condition
- ADHD
Study Drug
- Drug: Centanafadine SR
Date
Jan 2019 - May 2020
Phase 1/2
Phase 2/3
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 55 Years
Requirements Information
Protocol Summary
This study evaluated the efficacy, safety, and tolerability of centanafadine sustained-release tablets in adults with ADHD. Participants either received a twice-daily dose of centanafadine sustained-release tablets, or twice-daily placebo.
Study Locations
Location
Status
Location
For additional information regarding sites, contact 844-687-8522
Orlando, Florida, United States, 32806
Status
N/A
© 2025 Otsuka America Pharmaceutical, Inc.
All rights reserved.
July 2025 01US25EUC0279